Non-homogenous intratumor ionizing radiation doses synergize with PD1 and CXCR2 blockade.

Autor: Bergeron P; Gustave Roussy, INSERM U1030, Université Paris-Saclay, Villejuif, France., Dos Santos M; Institut de Radioprotection et de Sûreté Nucléaire (IRSN), PSE-SANTE/SERAMED/LRAcc, Fontenay-aux-Roses, France., Sitterle L; Gustave Roussy, INSERM U1030, Université Paris-Saclay, Villejuif, France., Tarlet G; Institut de Radioprotection et de Sûreté Nucléaire (IRSN), PSE-SANTE/SERAMED/LRMed, Fontenay-aux-Roses, France., Lavigne J; Institut de Radioprotection et de Sûreté Nucléaire (IRSN), PSE-SANTE/SERAMED/LRMed, Fontenay-aux-Roses, France., Liu W; Gustave Roussy, INSERM U1030, Université Paris-Saclay, Villejuif, France., Gerbé de Thoré M; Gustave Roussy, INSERM U1030, Université Paris-Saclay, Villejuif, France., Clémenson C; Gustave Roussy, INSERM U1030, Université Paris-Saclay, Villejuif, France., Meziani L; Gustave Roussy, INSERM U1030, Université Paris-Saclay, Villejuif, France., Schott C; Gustave Roussy, INSERM U1030, Université Paris-Saclay, Villejuif, France., Mazzaschi G; Gustave Roussy, INSERM U1030, Université Paris-Saclay, Villejuif, France., Berthelot K; Gustave Roussy, INSERM U1030, Université Paris-Saclay, Villejuif, France., Benadjaoud MA; Institut de Radioprotection et de Sûreté Nucléaire (IRSN), PSE-SANTE/SERAMED, Fontenay-aux-Roses, France., Milliat F; Institut de Radioprotection et de Sûreté Nucléaire (IRSN), PSE-SANTE/SERAMED/LRMed, Fontenay-aux-Roses, France., Deutsch E; Gustave Roussy, INSERM U1030, Université Paris-Saclay, Villejuif, France., Mondini M; Gustave Roussy, INSERM U1030, Université Paris-Saclay, Villejuif, France. michele.mondini@gustaveroussy.fr.
Jazyk: angličtina
Zdroj: Nature communications [Nat Commun] 2024 Oct 14; Vol. 15 (1), pp. 8845. Date of Electronic Publication: 2024 Oct 14.
DOI: 10.1038/s41467-024-53015-9
Abstrakt: The efficacy and side effects of radiotherapy (RT) depend on parameters like dose and the volume of irradiated tissue. RT induces modulations of the tumor immune microenvironment (TIME) that are dependent on the dose. Low dose RT (LDRT, i.e., single doses of 0.5-2 Gy) has been shown to promote immune infiltration into the tumor. Here we hypothesize that partial tumor irradiation combining the immunostimulatory/non-lethal properties of LDRT with cell killing/shrinkage properties of high dose RT (HDRT) within the same tumor mass could enhance anti-tumor responses when combined with immunomodulators. In models of colorectal and breast cancer in immunocompetent female mice, partial irradiation (PI) with millimetric precision to deliver LDRT (2 Gy) and HDRT (16 Gy) within the same tumor induces substantial tumor control when combined with anti-PD1. Using flow cytometry, cytokine profiling and single-cell RNA sequencing, we identify a crosstalk between the TIME of the differentially irradiated tumor volumes. PI reshapes tumor-infiltrating CD8 + T cells into more cytotoxic and interferon-activated phenotypes but also increases the infiltration of pro-tumor neutrophils driven by CXCR2. The combination of the CXCR2 antagonist SB225002 with PD1 blockade and PI improves tumor control and mouse survival. Our results suggest a strategy to reduce RT toxicity and improve the therapeutic index of RT and immune checkpoint combinations.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: